Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr100.00 DKK
Change Today +2.00 / 2.04%
Volume 47.5K
ZEAL On Other Exchanges
Symbol
Exchange
Copenhagen
Berlin
OTC US
OTC US
As of 11:06 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

zealand pharma a/s (ZEAL) Snapshot

Open
kr98.50
Previous Close
kr98.00
Day High
kr100.50
Day Low
kr98.50
52 Week High
03/23/15 - kr122.00
52 Week Low
10/16/14 - kr58.00
Market Cap
2.3B
Average Volume 10 Days
110.6K
EPS TTM
kr-2.87
Shares Outstanding
23.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZEALAND PHARMA A/S (ZEAL)

Related News

No related news articles were found.

zealand pharma a/s (ZEAL) Related Businessweek News

No Related Businessweek News Found

zealand pharma a/s (ZEAL) Details

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.

103 Employees
Last Reported Date: 03/13/15
Founded in 1998

zealand pharma a/s (ZEAL) Top Compensated Officers

Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: kr2.1M
Compensation as of Fiscal Year 2014.

zealand pharma a/s (ZEAL) Key Developments

Zealand Pharma A/S Announces Management Changes

Zealand Pharma A/S, at the annual general meeting, approved that Daniël Jan Ellens, Chairman and Jørgen Lindegaard, Vice Chairman did not stand for re-election. Catherine Moukheibir, Martin Nichlasson and Rosemary Crane, with Catherine Moukheibir as new Chairman, will comprise the Audit Committee. Martin Nicklasson, Mike J. Owen and Peter Benson, with Martin Niclasson as new Chairman, will comprise the Remuneration and Compensation Committee.

Zealand Pharma A/S, Board Meeting, Apr 11, 2015

Zealand Pharma A/S, Board Meeting, Apr 11, 2015.

Zealand Pharma A/S, Board Meeting, Mar 25, 2015

Zealand Pharma A/S, Board Meeting, Mar 25, 2015. Agenda: To adopt new provisions in accordance with Article 8.1 of the Articles of Association concerning the issuing of warrants to certain employees of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZEAL:DC kr100.00 DKK +2.00

ZEAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZEAL.
View Industry Companies
 

Industry Analysis

ZEAL

Industry Average

Valuation ZEAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.9x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZEALAND PHARMA A/S, please visit zealandpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.